Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy

Drug and Alcohol Dependence

Volumn 48, Issue 3, 1997, Pages 159-165

  Gorelick, David A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Butyrylcholinesterase; Cocaine; Metabolites; Pharmacokinetics

Indexed keywords

CHOLINESTERASE; COCAINE;

BEHAVIOR; DRUG DEPENDENCE; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

PRIMATES; RODENTIA;

EID: 0030735986     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(97)00119-1     Document Type: Article

References (60)

1. Ashani Y., Shapira S., Levy D., Wolfe A.D., Doctor B.P., Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem. Pharmacol. 41:1991;37-41.
2. Bagasra O., Forman L.J., Howeedy A., Whittle P. A potential vaccine for cocaine abuse prophylaxis. Immunopharmacol. 23:1992;173-179.
3. Borne R.F., Bedford J.A., Buelke J.L., Craig C.B., Hardin T.C., Kibbe A.H., Wilson M.C. Biological effects of cocaine derivatives I: improved synthesis and pharmacological evaluation of norcocaine. J. Pharm. Sci. 66:1977;119-120.
4. Brandeis R., Raveh L., Grunwald J., Cohen E., Ashani Y. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacol. Biochem. Behav. 46:1993;889-896.
5. Broomfield C.A., Maxwell D.M., Solana R.P., Castro C.A., Finger A.V., Lenz D.E. Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J. Pharmacol. Exp. Ther. 259:1991;633-638.
6. Browne S.P., Slaughter E.A., Couch R.A., McLean A.M. The influence of BChE concentration on the in-vitro hydrolysis of cocaine in human plasma. Pharmacol. Res. 12:1995;374.
7. Brzezinski M.R., Abraham T.L., Stone C.L., Dean R.A., Bosron W.F. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem. Pharmacol. 48:1994;1747-1755.
8. Carmona G.N., Baum I., Schindler C.W., Goldberg S.R., Jufer R.et al. Plasma butyrylcholinesterase activity and cocaine half-life differ significantly in rhesus and squirrel monkeys. Life Sci. 59:1996;939-943.
9. Carrera M.R.A., Ashley J.A., Parsons L.H., Wirsching P., Koob G.F., Janda K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature. 378:1995;727-730.
10. Chatonnet A., Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 260:1989;625-634.
11. Cohen P.J. Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug Alcohol Depend. 48:1997;167-174.
12. Crumb W.J., Clarkson C.W. Characterization of the sodium channel blocking properties of the major metabolites of cocaine in single cardiac myocytes. J. Pharmacol. Exp. Ther. 261:1992;910-917.
13. Dean R.A., Zhang J., Brzezinski M.R., Bosron W.F. Tissue distribution of cocaine methyl esterase and ethyl transferase activities: correlation with carboxylesterase protein. J. Pharmacol. Exp. Ther. 275:1995;965-971.
14. Delaney K., Hoffman R.S. Effects of cocaine on the in vitro determination of plasma cholinesterase activity: analysis of kinetics of inhibition. Vet. Hum. Toxicol. 33:1991;385.
15. Devenyi P. Cocaine complications and pseudocholinesterase. Ann. Intern. Med. 110:1989;167-168.
16. Doctor B.P., Raveh L., Wolfe A.D., Maxwell D.M., Ashani Y. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci. Biobehav. Rev. 15:1991;123-128.
17. Dretchen K.L., Singh A., Bradley R.M., Lynch T.J. Protection against cocaine toxicity by human butyrylcholinesterase (BChE) in rats. FASEB J. 6:1992;A1282.
18. Fox B.S. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend. 48:1997;153-158.
19. Fox B.S., Kantak K.M., Edwards M.A., Black K.M., Bollinger B.K., Botka A.J. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Med. 2:1996;1129-1132.
20. Garry P.J., Prince L.C., Notari R.E. Half-life of human serum cholinesterase following blood transfusion. Res. Commun. Chem. Pathol. Pharmacol. 8:1974;371-380.
21. Gatley S.J. Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem. Pharmacol. 41:1991;1249-1254.
22. Genovese R.F., Doctor B.P. Behavioral and pharmacological assessment of butyrylcholinesterase in rats. Pharmacol. Biochem. Behav. 51:1995;647-654.
23. Goedde H.W., Altland K., Schloot W. Therapy of prolonged apnea after suxamethonium with purified pseudocholinesterase: new data on kinetics of the hydrolysis of succinylcholine and succinylmonocholine and further data on N-acetyltransferase-polymorphism. Ann. N. Y. Acad. Sci. 151:1968;742-752.
24. Gorelick, D.A., 1995. Pharmacologic therapies for cocaine addiction. In: Miller, N.S., Gold, M.S. (Eds.), Pharmacological Therapies for Drug and Alcohol Addictions. Marcel Dekker, New York, pp. 143-157.
25. Halikas J.A., Nugent S.M., Crosby R.D., Carlson G.A. 1990-1991 Survey of pharmacotherapies used in the treatment of cocaine abuse. J. Addict. Dis. 12:1994;125-134.
26. Hoffman R.S., Henry G.C., Howland M.A., Weisman R.S., Weil L., Goldfrank L.R. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann. Emerg. Med. 21:1992;247-253.
27. Hoffman R.S., Henry G.C., Wax P.M., Weisman R.S., Howland M.A., Goldfrank L.R. Decreased plasma cholinesterase activity enhances cocaine toxicity in mice. J. Pharmacol. Exp. Ther. 263:1992;698-702.
28. Hoffman R.S., Morasco M.S., Goldfrank L.R. Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. Clin. Toxicol. 34:1996;259-266.
29. Inaba T. Cocaine: pharmacokinetics and biotransformation in man. Can. J. Physiol. Pharmacol. 67:1989;1154-1157.
30. Jatlow P., Barash P.G., Van Dyke C., Radding J., Byck R. Cocaine and succinylcholine sensitivity: a new caution. Anesth. Analg. 58:1979;235-238.
31. Jenkins T., Balinsky D., Patient D.W. Cholinesterase in plasma: first reported absence in the Bantu; half-life determination. Science. 156:1967;1748.
32. Kambam J.R., Franks J.J., Mets B., Janicki P.K., Hickman R., van der Watt M. The effect of hepatectomy and plasma cholinesterase inhibition on cocaine metabolism and cardiovascular responses in pigs. J. Lab. Clin. Med. 124:1994;715-722.
33. Kamendulis L.M., Brzezinski M.R., Pindel E.V., Bosron W.F., Dean R.A. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther. 279:1996;713-717.
34. Klose R., Gustensohn G. Treatment of alkyl phosphate poisoning with purified serum cholinesterase. Prakt. Anasth. 11:1976;1-7.
35. Landry D.W., Zhao K., Yang G.X.-Q., Glickman M., Georgiadis T.M. Antibody-catalyzed degradation of cocaine. Science. 259:1993;1899-1901.
36. Madden J.A., Powers R.H. Effects of cocaine and cocaine metabolites on cerebral arteries in vitro. Life Sci. 47:1990;1109-1114.
37. Massoulie J., Pezzementi L., Bon S., Krejci E., Vellette F.-M. Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 41:1993;31-91.
38. Mattes C., Bradley R., Slaughter E., Browne S. Cocaine and butyrylcholinesterase (BChE): determination of enzymatic parameters. Life Sci. 13:1996;257-261.
39. Mattes C., Singh A., Bradley R., Dretchen K. Cardioprotective effects of butyrylcholinesterase (BChE), an antidote for cocaine-induced cardiotoxicity. FASEB J. 10:1996;A449.
40. Mets B., Virag L. Lethal toxicity from equimolar infusions of cocaine and cocaine metabolites in conscious and anesthetized rats. Anesth. Analg. 81:1995;1033-1038.
41. 3H]benzoylecgonine and pharmacological activity of some cocaine metabolites. J. Pharm. Pharmacol. 27:1975;784-786.
42. Morishima H.O., Abe Y., Matsuo M., Akiba K., Masaoka T., Cooper T.B. Gender-related differences in cocaine toxicity in the rat. J. Lab. Clin. Med. 122:1993;157-163.
43. Om A., Ellahham S., Ornato J.P., Picone C., Theogaraj J., Corretjer G.P., Vetrovec G.W. Medical complications of cocaine: possible relationship to low plasma cholinesterase enzyme. Am. Heart J. 125:1993;1114-1117.
44. Ostergaard D., Jensen F.S., Viby-Mogensen J. Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase. Anesthesiology. 82:1995;1295-1298.
45. Raveh L., Grunwald J., Marcus D., Papier Y., Cohen E., Ashani Y. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem. Pharmacol. 45:1993;2465-2474.
46. Roth L., Harbison R.D., James R.C., Tobin T., Roberts S.M. Cocaine hepatotoxicity: influence of hepatic enzyme inducing and inhibiting agents on the site of necrosis. Hepatology. 15:1992;934-940.
47. Schindler C.W., Carmona G.N., Goldberg S.R., Greig N.H., Cone E.J., Shoaib M., Preston K., Gorelick D.A. Influence of butyrylcholinesterase (BChE) on cocaine-induced motor activity in rats. Soc. Neurosci. Abstr. 22(Part 3):1996;1930.
48. Scholler K.L., Goedde H.W., Benkmann H.-G. The use of serum cholinesterase in succinylcholine apnoea. Can. Anaesth. Soc. J. 24:1977;396-400.
49. Schuh F.T. Serum cholinesterase: effect on the action of suxamethonium following administration to a patient with cholinesterase deficiency. Br. J. Anaesth. 49:1977;269-272.
50. Schwartz H.J., Johnson D. In vitro competitive inhibition of plasma cholinesterase by cocaine: normal and variant genotypes. Clin. Toxicol. 34:1996;77-81.
51. Soreq, H., Zakut, H., 1993. Human Cholinesterases and Anticholinesterases. Academic Press, San Diego, CA.
52. Stewart D.J., Inaba T., Tang B.K., Kalow W. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci. 20:1977;1557-1563.
53. Stewart D.J., Inaba T., Lucassen M., Kalow W. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin. Pharmacol. Ther. 25:1979;464-468.
54. Stovner J., Stadskleiv K. Suxamethonium apnoea terminated with commercial serumcholinesterase. Acta Anaesth. Scand. 20:1976;211-215.
55. Viby-Mogensen J. Succinylcholine neuromuscular blockade in subjects homozygous for atypical plasma cholinesterase. Anesthesiology. 55:1981;429-434.
56. Washington C., Woosley R., Dretchen K., Singh A., Montoya I., Carriero N., Gorelick D.A. Plasma butyrylcholinesterase activity in substance abusers. NIDA Res. Monogr. 153:1995;326.
57. Weinhold L., Gorelick D., Woosley R., Du F. Plasma pseudocholinesterase activity in cocaine-dependent humans. NIDA Res. Monogr. 132:1993;173.
58. Wilkins, J.N., Gorelick, D.A., 1994. Management of stimulant intoxication and withdrawal. In: Miller, N.S. (Ed.), Principles of Addiction Medicine, section XI, ch. 6, American Society of Addiction Medicine, Chevy Chase, MD.
59. Wolfe A.D., Blick D.W., Murphy M.R. Use of cholinesterases as pretreatment drugs for the protection of rhesus monkeys against soman toxicity. Toxicol. Appl. Pharmacol. 117:1992;189-193.
60. Yang G., Chun J., Arakawa-Uramoto H., Wang X., Gawinowicz M.A., Zhao K., Landry D.W. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J. Am. Chem. Soc. 118:1996;5881-5890.